Back to Search Start Over

Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts

Authors :
Frank R. Jirik
Susan E. Andrew
Latha Narayanan
Xiaoxin S. Xu
R. Michael Liskay
Agnes Baross-Francis
Peter M. Glazer
Kate Milhausen
Source :
Carcinogenesis. 21:1291-1296
Publication Year :
2000
Publisher :
Oxford University Press (OUP), 2000.

Abstract

DNA mismatch repair (MMR) deficiency leads to an increased mutation frequency and a predisposition to neoplasia. 'Knockout' mice deficient in the MMR proteins Msh2 and Pms2 crossed with mutation detection reporter (supF, lacI and cII) transgenic mice have been used to facilitate a comparison of the changes in mutation frequency and spectra. We find that the mutation frequency was consistently higher in Msh2-deficient mice than Pms2-deficient mice. The lacI target gene, which is highly sensitive to point mutations, demonstrated that both Msh2- and Pms2-deficient mice accumulate transition mutations as the predominant mutation. However, when compared with Msh2 -/- mice, lacI and cII mutants from Pms2-deficient mice revealed an increased proportion of +/-1 bp frameshift mutations and a corresponding decrease in transversion mutations. The supF target gene, which is sensitive to frameshift mutations, and the cII target gene revealed a strong tendency for -1 bp deletions over + I bp insertions in Msh2 -/- compared with Pms2 -/- mice. These data indicate that Msh2 and Pms2 deficiency have subtle but differing effects on mutation avoidance which may contribute to the differences in tumor spectra observed in the two 'knockout' mouse models. These variances in mutation accumulation may also play a role, in part, in the differences seen in prevalence of MSH2 and PMS2 germline mutations in hereditary non-polyposis colorectal cancer patients.

Details

ISSN :
14602180 and 01433334
Volume :
21
Database :
OpenAIRE
Journal :
Carcinogenesis
Accession number :
edsair.doi...........3e8d5d5ab90b66c779158be5f5384e01
Full Text :
https://doi.org/10.1093/carcin/21.7.1291